Cargando…

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score

OBJECTIVE: To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL, and develop a risk-stratification score model. METHODS: The data of 345 patients underwent transrectal ultrasound-guided prostate biopsy betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Dong, Li, Xuesong, Yu, Wei, He, Qun, Xin, Zhongcheng, Zhou, Liqun, Zhao, Chenglin, Wang, Rui, Wang, Huihui, Wang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842724/
http://dx.doi.org/10.21037/tau.2016.s189
_version_ 1782428580511219712
author Fang, Dong
Li, Xuesong
Yu, Wei
He, Qun
Xin, Zhongcheng
Zhou, Liqun
Zhao, Chenglin
Wang, Rui
Wang, Huihui
Wang, Xiaoying
author_facet Fang, Dong
Li, Xuesong
Yu, Wei
He, Qun
Xin, Zhongcheng
Zhou, Liqun
Zhao, Chenglin
Wang, Rui
Wang, Huihui
Wang, Xiaoying
author_sort Fang, Dong
collection PubMed
description OBJECTIVE: To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL, and develop a risk-stratification score model. METHODS: The data of 345 patients underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE), prostate volum (PV), magnetic resonance imaging (MRI) and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa) and high grade PCa (HGPCa, Gleason Score ≥Th. RESULTS: The median PSA was 7.15 (IQR 5.91–8.45) ng/mL. Overall 138 patients (40.0%) were shown to have PCa, including 100 patients (29.0%) with HGPCa. Smaller PV, elder age, MRI results and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to category patients into three risk groups, and the model performed good predictive sensitivity and specificity. CONCLUSIONS: The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making.
format Online
Article
Text
id pubmed-4842724
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-48427242016-05-09 AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score Fang, Dong Li, Xuesong Yu, Wei He, Qun Xin, Zhongcheng Zhou, Liqun Zhao, Chenglin Wang, Rui Wang, Huihui Wang, Xiaoying Transl Androl Urol Printed Abstracts OBJECTIVE: To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL, and develop a risk-stratification score model. METHODS: The data of 345 patients underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE), prostate volum (PV), magnetic resonance imaging (MRI) and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa) and high grade PCa (HGPCa, Gleason Score ≥Th. RESULTS: The median PSA was 7.15 (IQR 5.91–8.45) ng/mL. Overall 138 patients (40.0%) were shown to have PCa, including 100 patients (29.0%) with HGPCa. Smaller PV, elder age, MRI results and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to category patients into three risk groups, and the model performed good predictive sensitivity and specificity. CONCLUSIONS: The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making. AME Publishing Company 2016-04 /pmc/articles/PMC4842724/ http://dx.doi.org/10.21037/tau.2016.s189 Text en 2016 Translational Andrology and Urology. All rights reserved.
spellingShingle Printed Abstracts
Fang, Dong
Li, Xuesong
Yu, Wei
He, Qun
Xin, Zhongcheng
Zhou, Liqun
Zhao, Chenglin
Wang, Rui
Wang, Huihui
Wang, Xiaoying
AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title_full AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title_fullStr AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title_full_unstemmed AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title_short AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
title_sort ab189. prevalence and risk factors of prostate cancer in chinese men with psa 4–10 ng/ml underwent trus-guided prostate biopsy: the utilization of pamd score
topic Printed Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842724/
http://dx.doi.org/10.21037/tau.2016.s189
work_keys_str_mv AT fangdong ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT lixuesong ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT yuwei ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT hequn ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT xinzhongcheng ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT zhouliqun ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT zhaochenglin ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT wangrui ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT wanghuihui ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore
AT wangxiaoying ab189prevalenceandriskfactorsofprostatecancerinchinesemenwithpsa410ngmlunderwenttrusguidedprostatebiopsytheutilizationofpamdscore